ERC Advanced Grant · 2020
Targeting DNA repair pathways, sparking anti cancer immunity
This project will test for the first time the hypothesis that therapeutic inactivation of DNA repair pathways in cancer cells can be exploited for patient benefit by reawakening an anti-tumor immune response. Genomic instability and molecular heterogeneity, which occur in cancer cells with DNA repair deficiencies, fuel tumour progression and are associated with poor outcome. An exception is represented by Mismatch repair (MMR) deficient cancers as these tumours are exceedingly genetically heterogeneous but show favourable prognosis and remarkable response to immunotherapy. The molecular basis for the clinical outcome of MMR deficient cancers has long remained a mystery. Only recently it has…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.